Abiopharma

🔍 North Run Strategic Opportunities Fund I, LP (Director)

Company: LIGHTPATH TECHNOLOGIES INC (LPTH)

Report Date: 2026-03-24

Detailed Transactions and Holdings:

• Sold 54,557 shares of Class A Common Stock at $12.06 per share (Direct)
  Date: 2026-03-24 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,845,516.00 | transaction_form_type: 4 | Footnotes: F2, F1
• Acquired 740,000 shares of Class A Common Stock at $2.15 per share (Direct)
  Date: 2026-03-25 | Code: C | equity_swap_involved: 0 | shares_owned_after: 3,585,516.00 | transaction_form_type: 4 | Footnotes: F4, F1
• Sold 302,352 shares of Class A Common Stock at $12.31 per share (Direct)
  Date: 2026-03-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 3,283,164.00 | transaction_form_type: 4 | Footnotes: F3, F1
• Sold 740,000 shares of Series G Convertible Preferred Stock at $2.15 per share (Derivative)
  Date: 2026-03-25 | Code: C | Exercise: 2025-02-18 | equity_swap_involved: 0 | shares_owned_after: 14,171.59 | transaction_form_type: 4 | Footnotes: F4, F4, F5, F1

Footnotes:

• F1: The reported securities are directly held by North Run Strategic Opportunities Fund I, LP, and may be deemed to be indirectly beneficially owned by North Run Strategic Opportunities Fund I GP, LLC as the general partner of North Run Strategic Opportunities Fund I, LP. The reported securities may also be deemed to be indirectly beneficially owned by Thomas B. Ellis and Todd B. Hammer as members of North Run Strategic Opportunities Fund I GP, LLC.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.0203 to $12.1413 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.72074 inclusive.
• F4: On March 25, 2026, the reporting persons converted 1,591 shares of the Issuer's Series G Convertible Preferred Stock into 740,000 shares of Class A Common Stock at a conversion price of $2.15 per share. No cash consideration was paid in connection with the conversion.
• F5: The preferred stock is perpetual and therefore has no expiration date.